Extranodal natural killer/T-cell lymphoma from skin or soft tissue: Suggestion of treatment from multinational retrospective analysis

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2703-2707

  Ahn, H K ^a   Suh, C ^b   Chuang, S S ^c   Suzumiya, J ^d   Ko, Y H ^a   Kim, S J ^a   Huh, J R ^b   Yoon, D H ^c   Oh, S Y ^e   Kim, J S ^f   Lee, S I ^g   Park, K W ^g   Hsieh, P P ^h   Nakamura, S ⁱ   Yoshino, T ^j   Ito, K ^k   Nagatani, T ^l   Oshimi, K ^m   Suzuki, R ⁱ   Kim, W S ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Dong A University College of Medicine   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Dankook University College of Medicine   (South Korea)

^h KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j OKAYAMA UNIVERSITY   (Japan)

^k NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^l YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^m JUNTENDO UNIVERSITY   (Japan)

more..

Author keywords

Chemotherapy; Extranodal NK T cell lymphoma; Prognosis; Radiation therapy; Skin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; ETOPOSIDE DERIVATIVE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; ELECTRON THERAPY; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; INTERNATIONAL SOCIETY FOR CUTANEOUS LYMPHOMAS-EUROPEAN ORGANIZATION OF RESEARCH AND TREATMENT OF CANCER TNM; KOREAN PROGNOSTIC INDEX SCORE; MALE; MONOTHERAPY; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SKIN LYMPHOMA; SOFT TISSUE TUMOR; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 84867130407     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds096     Document Type: Review

References (22)

1. Swerdlow SH, Campo E, Harris NL et al. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. lyon:IARC 2008.
2. Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 3931-3937.
3. Kim TM, Lee SY, Jeon YK et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008; 19: 1477-1484.
4. Lee J, Park YH, Kim WS et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 1402-1408.
5. Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.
6. Lee J, Suh C, Kang HJ et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008; 19: 2079-2083.
7. Kinoshita T, Hotta T, Tobinai K et al. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. Int J Hematol 2004; 80: 341-350.
8. Ezzat AA, Khalifa F, Berry J et al. E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Ann Oncol 1994; 5: 453-456.
9. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
10. Lee KW, Yun T, Kim DW et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/ T-cell lymphoma. Leuk Lymphoma 2006; 47: 1274-1282.
11. Suzuki R, Suzumiya J, Yamaguchi M et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010; 21: 1032-1040.
12. Choi YL, Park JH, Namkung JH et al. Extranodal NK/T-cell lymphoma with cutaneous involvement: 'nasal' vs. 'nasal-type' subgroups-a retrospective study of 18 patients. Br J Dermatol 2009; 160: 333-337.
13. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: longterm treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216-221.
14. Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasaltype: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618.
15. Yamaguchi M, Suzuki R, Kwong YL et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 1016-1020.
16. Kim WS, Song SY, Ahn YC et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol 2001; 12: 349-352.
17. Yamaguchi M, Kwong YL, Kim WS et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/ T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group Study. J Clin Oncol 2011; 29(33): 4410-4416.
18. Isobe K, Uno T, Tamaru J et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106: 609-615.
19. You JY, Chi KH, Yang MH et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15: 618-625.
20. Kim GE, Cho JH, Yang WI et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54-63.
21. Kim SJ, Kim K, Kim BS et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009; 27: 6027-6032.
22. Yamaguchi M, Tobinai K, Oguchi M et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009; 27: 5594-5600.